Sanofi Delay Boosts Novo's Bid For Insulin Dominance
This article was originally published in The Pink Sheet Daily
The delay to Sanofi's insulin/GLP-1 combo may help Novo push Lantus off the top-spot.
You may also be interested in...
The repercussions of FDA’s 2008 guidance on cardiovascular risk evaluation in diabetes trials are still being felt in reviews of new agents. CV concerns earned Novo Nordisk’s long-acting basal insulin a “complete response” letter. Pending applications include two GLP-1 agonists and a possible first-in-class SGLT-2 inhibitor, and safety is a major review issue for all of them.
For a single $110 million payment, the soon-to-be-split Abbott gets global rights to AP214, a Phase IIb compound designed to prevent acute kidney damage caused by hypoxia during cardiac surgery.
Market-leader Novo is confident it can continue to innovate in insulin – and command premium prices